Acetylcholinesterase Inhibitors | Community Health

Acetylcholinesterase inhibitors (AChEIs) are a class of drugs that prevent the breakdown of the neurotransmitter acetylcholine, thereby increasing its levels and duration of action in the central nervous system, autonomic ganglia, and neuromuscular junctions. This mechanism of action has significant implications for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and myasthenia gravis. With a rich history dating back to the early 20th century, AChEIs have evolved to include reversible, irreversible, and quasi-irreversible agents, each with its unique characteristics and applications. As research continues to uncover the complexities of the cholinergic system, AChEIs remain a vital tool in the management of neurological and psychiatric conditions, with over 10 million patients worldwide benefiting from these medications. The development of AChEIs has been shaped by the contributions of prominent researchers, including [[aricept|Aricept]] developer [[martin-rossor|Martin Rossor]] and [[exelon|Exelon]] developer [[novartis|Novartis]].